CQDM congratulates Variational AI (VAI) on announcing a major two-year partnership with Merck, valued at up to USD $349 million. This collaboration aims to accelerate the discovery of new medicines using Enki™, VAI’s cutting-edge generative artificial intelligence platform. CQDM is proud to have played a pivotal role in launching this journey through its Quantum Leap…
The CQDM is pleased to highlight the recent achievements of one of its members, Glycovax Pharma, a Montreal-based biopharmaceutical company specializing in glyco-immunology and the development of semi-synthetic vaccines. On one hand, Glycovax is launching large-scale production of the SLA vaccine adjuvant, an innovative compound developed by the National Research Council of Canada (NRC), which…
The call for applications for the 2025 Hippocrates Awards is officially open. These awards aim to recognize and highlight innovative initiatives in the field of health and social services in Québec. Are you part of an interdisciplinary or cross-sectoral team leading a forward-thinking project? Now is the time to showcase your work! The Hippocrates Awards…
This partnership was made possible through a CQDM Connect-Pharma call for proposals, an initiative that gives Canadian companies and researchers the opportunity to directly engage with CQDM’s international pharmaceutical members.CQDM plays a unique role as a facilitator of healthcare innovation, going well beyond financial investment. Thanks to its strong connections with major pharmaceutical players and…
Congratulations to Synucure Therapeutics, which has just completed a $2.8 million financing round, with 50% of the funding coming from the Government of Québec through Investissement Québec as part of the Impulsion PME program.👏CQDM is proud to have supported this project by acting as an advisor and referring entity, helping facilitate access to this crucial…
The CQDM is proud to join forces with the 8 other RSRI (Sectoral Industrial Research Groups) to deliver a strong message with one unified voice:Innovation is the key to ensuring the resilience and competitiveness of our Quebec businesses.The collaboration between research and industry is essential to transform ideas into concrete solutions. In a context where…
Ouverture de l’appel à solutions AReNA est heureux d’annoncer le lancement du premier appel à solutions de la CELLULE. Cette nouvelle approche d’accompagnement et de financement des innovations permettra d’accélérer le développement de technologies hautement prometteuses ayant le potentiel de résoudre certaines problématiques industrielles d’importance limitant actuellement le développement et l’utilisation des thérapies ARN. Les…
Montréal, le 11 juin 2024 – Le CQDM est fier d’annoncer la création du Réseau de développement et de production de thérapies ARN qui offrira des services de biofabrication en thérapies ARN aux chercheurs académiques et industriels. Mené par l’Institut de recherches cliniques de Montréal (IRCM), l’Université McGill et l’Université Sherbrooke, ce Réseau s’inscrit parmi…
Cette nouvelle initiative sera mise en œuvre avec l’appui et l’expertise de Axelys Montréal, le 6 juin 2024 – Le CQDM est heureux d’annoncer le lancement d’une nouvelle initiative ambitieuse visant à stimuler l’innovation et l’entrepreneuriat dans la filière de l’ARN thérapeutique au Québec. Menée par Axelys, en collaboration avec plusieurs partenaires, cette initiative s’inscrit…
San Diego, California – June 3rd, 2024 – CQDM, in collaboration with Axelys, Montréal InVivo and RNA Québec is proud to introduce AReNA, the new Québec’s RNA Hub. Unveiled at the BIO conference in San Diego, in the presence of the Minister for the Economy, the Minister responsible for the Fight Against Racism, and the…